HIV - associated and non - HIV associated types of Kaposi's sarcoma in an African population in Tanzania. Status of immune suppression and HHV-8 seroprevalence

European Journal of Dermatology

Volumn 16, Issue 6, 2006, Pages 677-682

  Wamburu, G ^a   Masenga, E J ^a   Moshi, E Z ^a   Schmid Grendelmeier, P ^b   Kempf, W ^b   Orfanos, C E ^c  

^a KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c RDTC ^*  (Germany)

Author keywords

African endemic KS; Epidemic KS; HHV 8; HIV; Kaposi's sarcoma

Indexed keywords

CD8 ANTIGEN; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AFRICA; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDEMIC DISEASE; FEMALE; HISTOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; PREVALENCE; SCHOOL CHILD; SEROLOGY; SEROPREVALENCE; TANZANIA;

ADOLESCENT; ADULT; ANTIGENS, CD8; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SARCOMA, KAPOSI; SEROEPIDEMIOLOGIC STUDIES; T-LYMPHOCYTES; TANZANIA;

EID: 33846827178     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0015     Document Type: Article

References (42)

1. National Guidelines for Clinical Management of HIV/AIDS. The United Republic of Tanzania, Ministry of Health, April 2002.
2. Modlin RL, Crissey JT, Rea T. Kaposi's sarcoma. Int J Dermatol 1983; 22: 443-6.
3. Friedman-Kien AE, Saltzman B. Clinical manifestations of classical, endemic, African and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol 1990; 22: 1237-50.
4. Tappero JW, Conant MA, Wolfe SF, et al. Kaposi's sarcoma epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993; 28: 371-85.
5. Schwartz RA. Kaposi's Sarcoma, advances and perspectives. J Am Acad Dermatol 1996; 34: 804-8.
6. Onyango JF, Njiru A. Kaposi's sarcoma in a Nairobi Hospital. East Afri Med J 2004; 81: 120-3.
7. Dedicoat M, Newton K. Review of the distribution of KSHV in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer 2003; 88: 1-3.
8. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16: 468-76.
9. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies, an international perspective. Hematol Oncol Clin North Am 2003; 17: 673-96.
10. Ocheni S. Aken'Ova YA: Association between HIV/AIDS and malignancies in a Nigerian tertiary institution. West Afri J Med 2004; 23: 151-5.
11. Cook-Mozaffari P, Newton R, Beral V, et al. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer 1998; 78: 1521-8.
12. Sitas F, Newton R. Kaposi's sarcoma in South Africa. J Natl Cancer Inst Monog 2001: 1-4.
13. Newton R, Ziegler J, Bourboulia D, et al. Infection with Kaposi's sarcoma associatea herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda. Br J Cancer 2003; 4(89): 502-4.
14. Craighaed J, Moore A, Grossman H, et al. Pathogenetic role of HIV infection in Kaposis' sarcoma in Equatorial East Africa. Arch Pathol Lab Med 1988; 112: 259-65.
15. Searles GE, Markman S, Yazdi HM. Primary oral Kaposi's sarcoma of the hard palate. J Am Acad Dermatol 1990; 23: 518-9.
16. Gross JD, Safai B. Kaposi's sarcoma /Aids cofactors. Int J Dermatol 1989; 28: 571-3.
17. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16: 468-76.
18. Pantanowitz L, Dezube BJ. Advances in pathobiology and treatment of Kaposi's sarcoma. Curr Opin Oncol 2004; 16: 443-9.
19. Boue F, Lebbe C. Kaposi's sarcoma. Bull Cancer 2003; 90: 393-8.
20. Cheung TW. AIDS -related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus and cancer. "On the offensive- the Trojan horse is being destroyed".Part A: Kaposi's sarcoma. Cancer Invest 2004; 22: 774-86.
21. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi's sarcoma associated virus (KSHV) infectivity. Blood 2004; 104: 810-4.
22. Bourboulia D, Aldam D, Lagos D, et al. Short and long term effects of highly active antiretroviral therapy on Kaposi's sarcoma-associated herpes virus immune responses and viraemia. AIDS 2004; 20(18): 485-93.
23. Gallafent JH, Buskia SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol 2005; 20(23): 1253-60.
24. Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004; 87: 146-51.
25. Inoue N, Spira T, Lam L, et al. Comparison of serologic responses between KS positive and negative men who were seropositive for both HHV-8 and HIV. J Med Virol 2004; 74: 202-6.
26. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi' s sarcoma in patients with HIV 1994-2003: the EuroSida study. Cancer 2004; 100: 2644-54.
27. Catlelan AM, Trevenzoli M, Aversa SM. Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma. Expert Opin Invest Drugs 2004; 13: 501-13.
28. Pedram G, Omeed M, Iris A, et al. Kaposi's Sarcoma and other manifestations of Human Herpesvirus. J Am Acad Dermatol 2002; 47: 641-51.
29. Friedman-Kien AE, Ostreicher R, Saltzman B. Clinical manifestations of classical, endemic, african and epidemic AIDS-associated Kaposi's sarcoma. In: Colour Atlas of AIDS. Philadelphia: Saunders, 1989: 11-81.
30. Cleste L, Felix A, Patricia C, et al. Detection of human herpevirus-8 and T cell lymphotropic virus type 1 sequences in Kaposi's sarcoma. Arch Dermatol 1997; 133: 25-9.
31. Dupin N, Rubin De Cervens V, Gorin I. The influence of highly active antiretroviral therapy on AIDS associated KS. Br J Dermatol 1999; 140: 875-80.
32. Schwartz EJ, Dorfman RF, Koeler S. Human Herpes Virus-8 latent nuclear antigen-1 expression in endemic Kaposi's sarcoma: An immunohistochemical study of 16 cases. Am J Surg Pathol 2003; 27: 1546-50.
33. Plancoulaine S, Abel L, Van Beveren M, et al. High titres of anti-human Herpes-8 antibodies in elderly males in an endemic population. J Natl Cancer Inst 2003; 94: 1333-5.
34. Jenson HB. Human Herpes virus-8 infection. Curr Opin Pediatr 2003; 15: 85-91.
35. Chandra A, Demirhan I, Massambu C, et al. Cross talk between human Herpesvirus-8 and the transactivator protein in the pathogenesis of Kaposi's sarcoma in HIV infected patients. Anticancer Res 2003; 23: 723-8.
36. Guo HG, Pati S, Sadowska M, et al. Tumorigenesis of human herpes virus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. J Virol 2004; 78: 9336-42.
37. Polstra AM, Cornelissen M, Goudsmit J, et al. Retrospective, longitudinal analysis of serum HHV-8 viral load DNA in AIDS- related KS patients before and after diagnosis. J Med Virol 2004; 74: 390-6.
38. Alagiozoglou L, Morris L, Bredell H, et al. Human herpes virus 8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect 2003; 131: 1125-9.
39. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpes virus 8 peripheral viral load and Kaposi's sarcoma clinical stage. AIDS 2000; 14: 2109-16.
40. Shwartz RA, Cohen JB, Ankami RN, et al. Penile Kaposi's sarcoma preceded by chronic penile lymphoedema. Br J Dermatol 2002; 142: 153-6.
41. Ziegler JL, Simonart T, Snoeck R. Kaposi's sarcoma, oncogenic viruses and iron. J Clin Virol 2001; 20: 127-30.
42. Mhalu FS, Lyamuya E. Human immunodeficiency virus infection and AIDS in East Africa: Challenges and possibilities for prevention and control. East Afr Med J 1996; 73: 13-9.